ASND β€” ASCENDIS PHARMA A S

Ownership history in PERCEPTIVE ADVISORS LLC  Β·  13 quarters on record

This page tracks every 13F SEC filing in which PERCEPTIVE ADVISORS LLC reported a position in ASCENDIS PHARMA A S (ASND). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β€” sourced directly from SEC EDGAR 13F filings.

πŸ” Peak position
6.25% (2025 Q3)
πŸ“Š Avg. % of fund
2.31%
πŸ“… First filed
2015 Q1
πŸ“… Last filed
2025 Q4
⏱ Quarters held
13

Position Intelligence

PERCEPTIVE ADVISORS LLC Γ— ASND AI Analytics

πŸ“ˆ PERCEPTIVE ADVISORS LLC outperformed the S&P 500 by +84.9% annually on this ASND position. Timing score: 70% (7/10 decisions correct). Average cost basis: $117.10. Maximum drawdown during holding period: –11.6%.

πŸ“ˆ Position Alpha vs SPY
+84.9%
annualised excess return

πŸ”₯ Exceptional β€” beat the S&P 500 by 84.9% per year on this position.
12 quarters analyzed

⏱️ Timing Score
70%

🎯 Smart timing β€” consistently buying dips and trimming near peaks.
7 of 10 add/trim decisions correct

πŸ’° Entry Quality
$117.10
+82.1% vs current ($213.24)

Best entry: $17.35 (2015 Q1)  Β·  Worst: $198.81 (2025 Q3)

πŸ›‘οΈ Drawdown Resilience
–11.6%
max drawdown while held

πŸ’Ž No drawdown exceeding 20% during the holding period β€” exceptionally stable.

πŸ’ͺ Fund Conviction
64%
buy-side decisions

7 adds Β· 4 trims. Bought during 1 of 2 down-price quarters. πŸ“ˆ More buys than sells across the holding period.

πŸ“‘ Position Trajectory
↑ Growing
last 4–5 quarters trend

πŸ“ˆ PERCEPTIVE ADVISORS LLC has been actively increasing its ASND allocation β€” a bullish signal from insiders.
Currently 4.11% of portfolio

⚠ Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ— 4 (annualised). Not investment advice.

% of Fund (quarterly)    ASND price (monthly, adj. close)
πŸ“‹ Quarterly Holdings History 10 quarters  β–Ύ
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 REDUCED 1,081,421 -7,080 -0.7% 4.11% $230.6M $213.24
2025 Q3 ADDED 1,088,501 +124,615 +12.9% 6.25% $216.4M $198.81
2025 Q2 ADDED 963,886 +831,710 +629.2% 6.17% $166.4M $172.60
2023 Q4 REDUCED 132,176 -341,299 -72.1% 0.37% $16.6M $125.95
2019 Q2 ADDED 473,475 +273,475 +136.7% 1.25% $54.5M $115.15
2019 Q1 REDUCED 200,000 -913,328 -82.0% 0.00% $25K $117.70
2019 Q1 ADDED 1,113,328 +60,681 +5.8% 3.70% $131.0M $117.70
2018 Q4 REDUCED 1,052,647 -20,000 -1.9% 2.40% $63.0M $62.65
2018 Q3 UNCHANGED 1,072,647 β€” 0% 2.03% $76.0M $70.86
2018 Q2 ADDED 1,072,647 +90,000 +9.2% 1.87% $71.4M $66.52
3 older quarters hidden  β€”  Sign in free or upgrade to Premium to see full history

🏒 Other funds also holding ASND

As of 2025 Q4 β€” sorted by position size

Q Global Advisors, LLC 3Y 7Y 39.86% RA CAPITAL MANAGEMENT, L.P. 3Y 7Y 22.46% Avoro Capital Advisors LLC 3Y 7Y 10.71% Resolute Capital Asset Partners LLC 3Y 9.13% Tri Locum Partners LP 3Y 7.34% WESTFIELD CAPITAL MANAGEMENT CO LP 3Y 7Y 4.61% Catalio Capital Management, LP 4.49% Spyglass Capital Management LLC 3Y 7Y 4.43% PFM Health Sciences, LP 3Y 7Y 3.78% First Turn Management, LLC 3.21%
← Back to PERCEPTIVE ADVISORS LLC Holdings